Sign inJoin waitlistJoin the waitlist

Matthew Block

Associate Professor of Oncology · Mayo Clinic College of Medicine and Science

Credentials: · · · · ·

History

Mayo Clinic College of Medicine and Science
Present
Mayo Clinic College of Medicine and Science
Present

Hematology and Medical Oncology
Mayo Clinic College of Medicine and Science
2010–2013
Mayo Clinic College of Medicine and Science
2008–2010
Internal Medicine
Mayo Clinic College of Medicine and Science
2005–2008
Mayo Clinic School of Medicine
2001–2005

Research

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
JAMA Oncology · 2017 · 353 citations
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma
PLoS Genetics · 2014 · 285 citations
Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes
BMJ Open Diabetes Research & Care · 2019 · 185 citations

Svetomir Markovic
32 papers
Lisa Kottschade
24 papers
Robert McWilliams
22 papers
Tina Hieken
20 papers
Roxana Dronca
14 papers
AJ
Aminah Jatoi
12 papers
Amanika Kumar
11 papers · 2 as a fellow
Carrie Langstraat
11 papers
Andrea Hendrickson
10 papers · 5 as a resident
AD
Anastasios Dimou
9 papers
James Jakub
9 papers
John Weroha
9 papers

Grants

A Phase I/II Study of Combined Therapy with Th17-Inducing Dendritic Cells and Pembrolizumab in Patients with Recurrent Epithelial Ovarian Cancer
National Cancer Institute · R01
PI · $2.5M · Mayo Clinic Jacksonville
2023–2028
Mayo Clinic Ovarian Cancer SPORE
National Cancer Institute · P50
Project lead · $438.4K · Mayo Clinic Rochester
2009–2026
A Novel Melanoma Vaccine Based on a Shared Neoantigen and a Liquid Polymer Platform
National Cancer Institute · R41
PI · $547.8K · Trekka Therapeutics, Llc
2023–2025
Phase I Trial of Intravenous Vesicular Stomatitis Virus for Treatment of Metastatic Endometrial Cancer
National Cancer Institute · R01
PI · $2.5M · Mayo Clinic Rochester
2017–2023

Clinical trials

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
Principal investigator · Recruiting · Phase 2
Mayo Clinic
2024–2027
Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors
Principal investigator · Withdrawn · Phase 1
Mayo Clinic
2024
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Principal investigator · Active not recruiting · Phase 1, Phase 2
Mayo Clinic
2023–2030
Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
Principal investigator · Completed · Phase 2
Mayo Clinic
2018–2025